Carregando...

Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?

BACKGROUND: Genetic variants of the warfarin sensitivity gene CYP2C9 have been associated with increased bleeding risk during warfarin initiation. Studies also suggest that such patients remain at risk throughout treatment. OBJECTIVE: Would testing patients with non-valvular atrial fibrillation (AF)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Eckman, Mark H., Greenberg, Steven M., Rosand, Jonathan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer-Verlag 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2669861/
https://ncbi.nlm.nih.gov/pubmed/19255811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11606-009-0927-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!